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Introduction
The etiology of the selective loss of hypocretin (orexin) 
neurons in the posterolateral hypothalamus in sporadic 
narcolepsy with cataplexy (NC) is not known. Because of 
the tight association of narcolepsy with certain human 
leukocyte antigen (HLA) alleles, an autoimmune mech-
anism is considered [1, 2]. Two groups recently reported 
on hypocretin-deficient NC patients, who experienced a 
significant and sustained reduction of frequency and 
severity of cataplexy after administration of high-dose 
intravenous immunoglobulins (IVIg), in particular 
when treated early after disease onset [3, 4, 8]. These 
findings seemed to corroborate the autoimmune hypo-
thesis and suggested that early IVIg treatment in NC 
might favorably modify the course of disease. 
In this report we describe four hypocretin-deficient 
NC patients without or with uncertain benefit from IVIg 
therapy.
Case 1
This 43-year-old woman noticed in summer 2004 the 
gradual appearance of daytime sleepiness with daily 
 irresistible and restorative naps. In December 2004 she 
experienced the first cataplectic attacks involving the 
head and both lower limbs, triggered by strong emo-
tions (mainly laughter), and occurring up to several 
times per day. Her night-time sleep was increasingly dis-
turbed by frequent awakenings, and dreams became 
more vivid and realistic. She also had rare episodes of 
(hypnagogic) hallucinations and sleep paralysis. Ep-
worth Sleepiness Scale (ESS) was 19/24, Ullanlinna Nar-
colepsy Score (UNS) 16/44, and Swiss Narcolepsy Scale 
(SNS) 36 [7, 10]. Clinical examination was unremark-
able. Magnetic resonance imaging (MRI) scan of the 
brain showed few, nonspecific, small (< 1 cm) hyperin-
tense signal alterations of the subcortical/white matter 
without gadolinium enhancement. Cerebrospinal fluid 
(CSF) examination revealed normal glucose and protein 
content, 5 mononuclear cells/μl, and no oligoclonal 
bands. CSF hypocretin-1 was undetectable (< 40 pg/ml). 
HLA typing was positive for DQB1*0602, DQA1*01, 
DRB1*15 and DRB5*. Polysomnography (PSG), multiple 
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■ Abstract  We report on four 
 patients with narcolepsy with 
 cataplexy (NC), who were treated 
with high-dose intravenous 
 immunoglobulins (IVIg). Although 
in some patients transient effects 
were seen of both objective (multi-
ple sleep  latency test and mainte-
nance of wakefulness test) and 
 subjective symptoms (Epworth 
Sleepiness Scale and frequency of 
cataplexy), these effects lasted at 
the most for a few weeks and did 
not persist. Our report challenges 
the recent observations of a favor-
able and persistent effect of IVIg in 
NC patients.
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sleep latency tests (MSLT; showing 4 sleep onset REM 
periods [SOREMP] in 5 tests) and maintenance of wake-
fulness tests (MWT; showing 2/4 SOREMPs) were con-
sistent with narcolepsy (Fig. 1). 
Methylprednisolone 1000 mg/d was administered in-
travenously for 3 consecutive days and then orally ta-
pered over 8 days. During the first 3 weeks after steroid 
treatment the patient reported a mild (10–20 % better as 
estimated by the patient) but only transient reduction of 
EDS and cataplexy. This prompted a trial with IVIg at a 
dose of 1 g/kg/day over 2 days, repeated three times at 
5-week intervals (latency from cataplexy onset: 4 
months). After the first two IVIg infusions, the patient 
reported a gradual improvement of EDS (decrease of 
ESS from 15–19/24 at baseline to 11/24 after the second 
IVIg trial) and a mild reduction of frequency of self-re-
ported cataplexy (measured by a cataplexy diary). How-
ever, after the third IVIg infusion, cataplexy and severity 
of EDS (ESS = 17/24) returned to pre-treatment levels. 
No effects were noted on hallucinations, sleep paralysis 
and MSLT/MWT results during and after IVIg (Fig. 2).
Case 2
This 59-year-old woman developed EDS and cataplectic 
attacks after a flu-like infection in 1987. She had 3–4 
short irresistible and restorative naps per day, her 
 cataplectic attacks affected mainly the head and neck, 
triggered by laughter, but also by negative emotions, oc-
curring up to 1–3 times/day. Acoustic (hypnagogic) hal-
lucinations occurred once a month, and a few years later 
she also developed rare episodes of sleep paralysis. Most 
drugs, including modafinil, methylphenidate, dexam-
phetamine and mazindol, were not tolerated. Fluoxetine 
had a moderate effect on cataplexy. 
MSLT
0
a
b
1
2
3
4
5
6
7
8
after II. IVIg
trial
after III. IVIg
trial 
m
ea
n 
sl
ee
p 
la
te
nc
y 
[m
in
]
patient 1
patient 2
patient 3
patient 4
MWT
0
2
4
6
8
10
12
baseline after II. IVIg
trial
after III. IVIg
trial 
m
ea
n 
sl
ee
p 
la
te
nc
y 
[m
in
]
patient 1
patient 2
patient 3
patient 4
after I. IVIg
trial
baseline after I. IVIg
trial
Fig. 1  a Multiple sleep latency test (MSLT) and b the maintenance of wakefulness 
test (MWT) at baseline and their response to IVIg treatment
0
1
2
3
4
5
6
7
baseline after II. IVIg
trial
after III. IVIg
trial
follow-up
ca
ta
pl
ec
tic
 a
tt
ac
ks
 p
er
 d
ay
patient 1
patient 2
patient 3
patient 4
0
b
a
4
8
12
16
20
24
ES
S 
[0
-2
4]
patient 1
patient 2
patient 3
patient 4
after I. IVIg
trial
baseline after II. IVIg
trial
after III. IVIg
trial
follow-upafter I. IVIg
trial
Fig. 2  a Frequency of self-reported cataplectic attacks and b Epworth Sleepiness 
Scale (ESS, measuring subjective sleepiness) at baseline and after each administra-
tion of intravenous immunoglobulins
1902
In August 2003 a common variable immunodefi-
ciency syndrome (deficiency of IgG subclasses II and IV, 
[9]) was diagnosed and a treatment with IVIg infusions 
of 20 g every 3 weeks was started.
In September 2004 we first saw the patient. ESS was 
20/24, UNS 30/44, and SNS –66. Clinical examination 
and brain MRI were unremarkable. Routine CSF exami-
nations were normal. CSF hypocretin-1 was undetect-
able. HLA-typing was positive for DQB1*0602, DQA1*01, 
DRB1*15 and DRB5*. Sleep-wake tests (PSG, MSLT with 
2/4 SOREMPs, MWT without SOREMPs) were typical 
for narcolepsy (Fig. 1).
Considering the failure of all previous medications 
and the diagnosis of a common-variable immunodefi-
ciency syndrome, additional treatment with high-dose 
IVIg infusions was started (latency from narcolepsy 
 onset: 17 years). Because of allergic reactions the usual 
dose (2 g/kg) was distributed over 5 days (and not as 
usual over 2 days). No effects were noted on EDS, cata-
plexy, hallucinations, sleep paralysis, and MSLT/MWT 
results during and after IVIg (which was stopped after 
the second administration because of recrudescence of 
allergy) (Fig. 1).
Case 3
This 41-year-old man developed EDS with irresistible 
naps within a few days in August 2004 while mastering 
an unusually stressful family situation. In the following 
months he experienced few generalized and several par-
tial clear-cut cataplectic attacks per day which were trig-
gered by laughing and other positive emotions, as well 
as occasional sleep paralysis and hypnagogic and hyp-
nopompic hallucinations. Night-time sleep became 
more fragmentary and his dreams intense and threaten-
ing. ESS was 22/24, UNS 29/44, and SNS –95. Clinical ex-
amination and brain MRI were unremarkable. Sleep-
wake tests were typical for narcolepsy, including 4/4 
SOREMPs in MSLT and 3/4 SOREMPs in MWT (Fig. 1). 
Repeated CSF examination showed a mild pleocytosis 
(4–10 mononuclear cells/μl), without oligoclonal bands. 
CSF hypocretin-1 was undetectable. HLA-typing was 
positive for DQB1*0602, DQA1*01, DRB1*15 and DRB5*. 
Extensive serologic and immunologic tests were nega-
tive. 
The combination of modafinil 100–200 mg b.i.d. with 
venlafaxine 75 mg completely controlled cataplectic at-
tacks, hallucinations and sleep paralysis and signifi-
cantly improved EDS (the ESS went from 22 to 15). He 
was able to return to work in full time position for 2.5 
years. In association with an increased psychosocial 
stress (divorce) and weight gain his narcoleptic symp-
toms exacerbated and became disabled despite several 
modifications of his medical therapy. This prompted 
treatment with IVIg infusions at a dose of 1 g/kg/day 
over 2 days, repeated three times at 5-week intervals (la-
tency disease onset: 4 years).
The patient reported a significant reduction in num-
ber and severity of cataplectic attacks from 3–4/d at 
baseline to 1–2/week after the second and 0–1/week 
 after the third IVIg infusion. The overall improvement 
of cataplexy was estimated to be around 80–90 %. How-
ever, during the short hospitalizations on occasion of the 
IVIg trials, the persistent occurrence of daily cataplectic 
attacks could be witnessed by several of us (POV, RK, 
CLB). There was also a strong improvement of subjec-
tive EDS, which the patient reported to recognize already 
within the first hour of the first IVIg infusion (reduction 
of ESS from 15–19/24 at baseline to 11/24 after the first 
IVIg). Objective parameters (MSLT, MWT), however, re-
mained unchanged. In the following weeks, the patient 
experienced also a progressive reappearance of narco-
leptic symptoms. Eight weeks after the last IVIg trial 
severity of EDS, cataplexy and sleep paralysis and hal-
lucinations were comparable to pre-treatment levels. 
Case 4
In June 2006 this 52-year-old woman developed EDS 
with irresistible need of 2–3 restorative naps/day and 
severe cataplectic attacks with falls, triggered by both 
positive and negative emotions, and occurring up to ten 
times per day. She did not notice any change of her 
night-time sleep, but her dreams became more intensive. 
She has never experienced any hypnagogic hallucina-
tions or sleep paralysis. ESS was 17/24, UNS 39/44, and 
SNS –92. Clinical examination and brain MRI were un-
remarkable. Routine CSF examination was normal. CSF 
hypocretin-1 was undetectable. HLA-typing was posi-
tive for DQB1*0602, DQA1*01, DRB1*15 and DRB5*. 
Sleep-wake tests were typical for narcolepsy, including 
2/4 SOREMPs in MSLT tests and 3/4 SOREMPs in MWT 
(Fig. 1). 
Treatment with modafinil 50 mg/d and fluoxetine 20 
mg/d was started, leading only to a mild improvement of 
both subjective EDS and cataplexy. Treatment with 
modafinil and fluoxetine was gradually tapered, and af-
ter a drug-free period of 3 weeks a trial with IVIg was 
started at a dose of 1 g/kg/day over 2 days, repeated three 
times at 5-week intervals (latency from cataplexy onset: 
11 months). No effects were noted on EDS, cataplexy, 
and MSLT/MWT results during and after IVIg treat-
ment.
Discussion
We report the absence of persistent improvements of 
narcoleptic symptoms in four patients treated with IVIg 
infusions. Although transient effects were seen concern-
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ing MSLT in patients 1 and 4, MWT in patient 3, cata-
plectic attacks in patient 3, and ESS in patients 1 and 3, 
these effects lasted at the most for a few weeks and did 
not persist. This observation is in contrast with the re-
cent reports by Dauvilliers, Lecendreux, and collegues, 
on five narcolepsy patients [3, 4, 8] in whom a sustained 
reduction in number and severity of cataplexy and a 
moderate effect on EDS (in all five patients) were 
achieved. The lack of a significant and persistent effect 
of intravenous steroids given early after onset of symp-
toms in one of our four patients also confirms the report 
of Mignot [6].
Four factors may account for the lack of significant 
effects of IVIg in our patients. First, only two of our pa-
tients were treated early after onset of cataplexy (four 
and eleven months, respectively, after the first appear-
ance of cataplectic attacks). However, one patient de-
scribed by Dauvilliers et al. was treated with IVIg with a 
delay of 9 years from disease onset, but reported im-
provement on both cataplexy and EDS with persistence 
of efficacy after 22 months without any anticataplectic 
or stimulant treatment. Second, in all of our patients CSF 
hypocretin-1 was already undetectable, suggesting that 
(presumed) autoimmune destruction of hypocretin 
neurons was already complete when IVIg therapy was 
started. However, all patients reported by Dauvilliers et 
al. had also undetectable CSF hypocretin-levels before 
IVIg treatment was started. Third, the treatment proto-
col was not identical in each patient, with patient 1 re-
ceiving corticosteroids and patient 2 receiving IVIg in 
lower dosages prior to the three IVIg trials. Fourth, our 
patients were older at disease onset (39, 40, 41 and 51 
years) than those reported by Dauvilliers et al. (10, 12, 21 
and 43 years). Both the efficacy of IVIg and the suscep-
tibility to placebo effects may significantly depend on 
the patient’s age at disease onset. 
The discrepancy between lack of objective improve-
ment (of EDS) and strong subjective improvement (of 
both cataplexy and EDS) in patient 1 and 3 suggest that 
a placebo effect might explain, at least in some cases, the 
improvement of narcoleptic symptoms (and particu-
larly cataplexy) after IVIg. Indeed, a similar observation 
was recently reported in a narcoleptic patient who un-
derwent a double-blind placebo-controlled administra-
tion of IVIg [5]. The authors could not find a difference 
between placebo and IVIg treatment. Furthermore, a re-
cent trial with sodium oxybate has proven the existence 
of a placebo effect on cataplexy [11].
Our report challenges the first, very optimistic obser-
vations on the favorable effects of IVIg in patients with 
narcolepsy with cataplexy [3, 4, 8], without proving the 
absence of any effect of IVIg (particularly on cataplexy). 
Only a randomized, double-blind and placebo-con-
trolled study with narcolepsy patients with both early 
and late disease onset could determine the “true” value 
of IVIg in the treatment of narcolepsy and the ideal in-
terval after onset of symptoms for this expensive and 
possibly harmful therapeutic intervention. 
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